

REMARKS

Status of the Claims

Claims 1-23 were pending in the application.

Claim 23 has been allowed.

Claims 10-13 and 22 have now been canceled.

Claims 4 and 14-20 are withdrawn from consideration as being directed to a non-elected invention. Certain withdrawn claims are amended to maintain their scope commensurate with presently-examined composition claims. MPEP § 821.04.

Claims 3, 4, 5 and 21 have been amended by replacing the phrase “represented by” with “as set forth in.” Support for the amendment can be found in the Sequence Listing.

No new matter has been added.

Rejections Under 35 USC § 112, Second Paragraph

The Examiner has rejected claims 3, 5, 21 and 22 as indefinite for recitation of the phrase “nucleotide sequence represented by” which is followed by a particular SEQ ID NO.

Applicants point out that claim 22 has been canceled, thereby obviating the rejection based upon that claim.

Applicants have amended claims 3, 5 and 21 by replacing “nucleotide sequence represented by” with the phrase “nucleotide sequence as set forth in,” as suggested by the Examiner. Thus Applicants request reconsideration and removal of the rejection.

The Examiner has rejected claim 22 as being unclear. Applicants have canceled claim 22, thereby obviating the rejection.

Rejections Under 35 USC § 103

The invention is not prima facie obvious over the combined references

The Examiner has rejected claims 1, 2, 6-9 and 22 as obvious over Ikeda et al. in view of Kato et al. The Examiner contends that Ikeda et al. describe selectable subgenomic RNAs derived from the HCV-N strain capable of self-replication in cultured human hepatocyte cell line Huh7 with selection for G418 resistance following transfection. Clones containing a 5' UTR, Neo gene, EMCV IRES, NS3, NS4A, NS4B, NS5A, NS5B and 3' UTR regions are described.

The Examiner states that while the HCV-N strain described by Ikeda et al. is a genotype 1b virus, HCV genotype 2a virus was characterized in the prior art, such as by Kato et al who describe the recovery, cloning and sequence analysis of HCV type 2a and of an isolate containing the 5'UTR, NS3, NS4A, NS5A, NS5B and 3'UTR regions.

The Examiner concludes that a skilled artisan would be motivated to combine the Ikeda et al. teachings with the HCV 2a genotype described by Kato et al. to produce subgenomic clones of HCV genotype 2a because this would allow the production of HCV 2a clones for analysis and characterization of replication competence. The Examiner further contends that the skilled artisan would have had a reasonable expectation of success. Applicants respectfully traverse.

As a preliminary matter, Applicants note that claim 22 has been canceled, thereby obviating the rejection of this claim.

The Examiner states “Applicants’ arguments with regard to the post-filing reference of Blight et al. are not found persuasive, because the reference is not one considered by a person of ordinary skill in the art at the time the invention was made.” Applicants point to the publication date for the Blight et al. publication, which is March 2003. The earliest priority date of the instant application is May 26, 2003, as evidenced by the copy of the Official Filing Receipt, attached to this response. Consequently, the Blight et al. reference was available to one of ordinary skill in the art prior to the instant invention.

Applicants again point out that Blight et al. provides evidence that attempts to extend the replication competency of HCV 1a and 1b to other genotypes were largely unsuccessful (see Blight et al., page 3181, column 2, lines 5-14). The Examiner is using hindsight in giving weight to a broad statement in Ikeda et al. (i.e. “Previous studies have demonstrated that subgenomic RNA replicons derived from diverse members of the family *Flaviviridae* are capable of autonomous replication in permissive cell lines”) and ignoring the statement in Blight et al. that attempts to extend replication competency of HCV beyond HCV 1a and 1 b to other genotypes were largely unsuccessful.

Here, Applicants note that while HCV type 2a is not specifically noted as “unsuccessful” by Blight et al., the fact that Blight et al. state attempts to extend to be “largely unsuccessful” would not instill “a reasonable expectation of success” in the skilled artisan without an affirmative statement that attempts using HCV type 2a would be successful.

Based on the above, Applicants submit that the Examiner has not made a prima facie case of obviousness. Consequently, Applicants respectfully request reconsideration and removal of the rejection.

The Examiner has rejected claim 3 as being obvious over Ikeda et al. in view of Kato et al. and further in view of JP 2002-171978. The Ikeda et al. and Kato et al. references are described above. The Examiner contends that JP 2002-171978 discloses in Sequence 1 of that document the sequences denoted in the instant application as SEQ ID NOS: 9 and 10. The Examiner concludes that that a skilled artisan would be motivated to combine the Ikeda et al. and Kato et al. teachings with the sequences disclosed in JP 2002-171978 because it would allow the production of HCV2a clones and would have a reasonable expectation of success. Applicants respectfully traverse.

Applicants discuss the Ikeda et al. and Kato et al. references above and note that these same facts and arguments apply to this rejection of claim 3. The disclosure of Sequence 1 in JP 2002-171978 fails to overcome the negative teachings and lack of an expectation of success, and thus fail to cure the void in the Examiner's argument. In other words, the disclosure of JP 2002-171978 does not provide the skilled artisan with any reason to expect anything but failure in producing subgenomic RNAs of genotype 2a. Consequently, Applicants respectfully request reconsideration and removal of the rejection.

***The invention provides results not expected by the skilled artisan
who reads the cited references***

Even if, *arguendo*, a *prima facie* case of obviousness is deemed established by the cited references, the claimed invention provides results that are unexpected by one of ordinary skill in the art who reads Ikeda et al. and Kato et al.

Specifically, Murayama et al. (2007) (copy attached) shows that a subgenomic RNA replicon of the JFH-1 strain of HCV genotype 2a has a significantly higher ability to autonomously replicate (i.e. more efficient replication) compared to those of other HCV genotype 2a strains J6CF, JCH-1 and JCH-4 (see, e.g. Figure 1). Further, Figure 4 of Murayama et al. (2007) shows that a subgenomic RNA replicon of the JFH-1 strain also has a significantly higher ability to replicate autonomously not only compared to strains JCH-1 and JCH-4 (genotype 2a), but also compared to H77c (genotype 1a) or Con1 (genotype 1b). Such higher efficiency of autonomous replication for the strain JFH-1 would be unexpected by one of ordinary skill in the art who reads Ikeda et al. and Kato et al. and provides objective evidence of unobviousness sufficient to establish patentability of the invention over the prior art of record.

Accordingly, the rejections of claims 1, 2, 3, 6-9 and 22 as obvious over Ikeda et al. in view of Kato et al. should be withdrawn.

Conclusion

In view of the above, all of the claims remaining in the case are submitted to be novel, non-obvious and patentable. Thus, Applicants believe the pending application is in condition for allowance.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Susan Gorman (Reg. No: 47,604), at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.


Application No. 10/558,155
Reply to Office Action of July 16, 2009
Reply dated October 16, 2009

Docket No.: 1254-0299PUS1

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37.C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Dated: October 16, 2009

Respectfully submitted,

By  #36,623
Susan W. Gorman
Registration No.: 47,604
BIRCH, STEWART, KOLASCH & BIRCH, LLP
12770 High Bluff Drive
Suite 260
San Diego, California 92130
(858) 792-8855
Attorney for Applicant

Enclosures: copy of Official Filing Receipt
Murayama et al., *J. Virology* 81:8030-8040 (2007)

The NS3 Helicase and NS5B-to-3'X Regions Are Important for Efficient Hepatitis C Virus Strain JFH-1 Replication in Huh7 Cells[∇]

Asako Murayama,¹ Tomoko Date,¹ Kenichi Morikawa,¹ Daisuke Akazawa,^{1,2} Michiko Miyamoto,³ Minako Kaga,¹ Koji Ishii,¹ Tetsuro Suzuki,¹ Takanobu Kato,^{4,5} Masashi Mizokami,⁴ and Takaji Wakita^{1*}

Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan¹; Pharmaceutical Research Lab, Toray Industries, Inc., Kanagawa, Japan²; Department of Microbiology, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan³; Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan⁴; and Liver Disease Branch, NIDDK, National Institutes of Health, Bethesda, Maryland⁵

Received 23 September 2006/Accepted 8 May 2007

The JFH-1 strain of hepatitis C virus (HCV) is a genotype 2a strain that can replicate autonomously in Huh7 cells. The J6 strain is also a genotype 2a strain, but its full genomic RNA does not replicate in Huh7 cells. However, chimeric J6/JFH-1 RNA that has J6 structural-protein-coding regions and JFH-1 nonstructural-protein-coding regions can replicate autonomously and produce infectious HCV particles. In order to determine the mechanisms underlying JFH-1 RNA replication, we constructed various J6/JFH-1 chimeras and tested their RNA replication and virus particle production abilities in Huh7 cells. Via subgenomic-RNA-replication assays, we found that both the JFH-1 NS5B-to-3'X (N5BX) and the NS3 helicase (N3H) regions are important for the replication of the J6CF replicon. We applied these results to full-length genomic RNA replication and analyzed replication using Northern blotting. We found that a chimeric J6 clone with JFH-1 N3H and N5BX could replicate autonomously but that a chimeric J6 clone with only JFH-1 N5BX had no replication ability. Finally, we tested the virus production abilities of these clones and found that a chimeric J6 clone with JFH-1 N3H and N5BX could produce infectious HCV particles. In conclusion, the JFH-1 NS3 helicase and NS5B-to-3'X regions are important for efficient replication and virus particle formation of HCV genotype 2a strains.

Hepatitis C virus (HCV) is a major cause of chronic liver disease (7, 22). The lack of a robust cell culture system for producing virus particles has hampered the development of HCV research (2). Although the development of a subgenomic-replicon system enabled research into HCV RNA replication (32), infectious-virus-particle production remained impossible. Recently, an HCV cell culture system was developed using a JFH-1 genotype 2a strain of HCV cloned from a fulminant hepatitis patient (30, 48, 54), allowing investigation of the virus life cycle.

HCV is a positive-strand RNA virus that belongs to the *Hepacivirus* genus in the *Flaviviridae* family. The HCV genome comprises about 9,600 nucleotides that encode a single polypeptide of around 3,000 amino acids (8, 18, 44), which is processed by cellular and viral encoded proteases into at least 10 different structural and nonstructural proteins (11, 13, 14, 33).

The JFH-1 strain of HCV is a genotype 2a strain, and it is the first HCV strain that can produce HCV particles in Huh7 cells (48). Subgenomic replicons of JFH-1 replicate efficiently in Huh7 cells and do not require cell culture-adaptive mutations (19). The J6CF strain of HCV is also a genotype 2a strain and is known to be infectious in chimpanzees (49), but its

entire genomic RNA does not replicate in Huh7 cells, despite the ~90% nucleotide sequence homology between JFH-1 and J6CF. However, J6/JFH-1 chimeric RNA that has J6 structural-protein-coding regions and JFH-1 nonstructural-protein-coding regions can replicate autonomously and produce infectious HCV particles (30, 39). Why only the JFH-1 clone can replicate efficiently in Huh7 cells remains unclear.

In this study, to investigate the mechanisms underlying efficient JFH-1 replication, we focused on the differences in replication between JFH-1 and J6CF strains by using intragenotypic JFH-1 and J6CF chimeras and compared their respective abilities to replicate RNA and produce virus particles in Huh7 cells.

MATERIALS AND METHODS

Cell culture. Huh7 cells (36) were cultured at 37°C in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum under 5% CO₂ conditions.

Subgenomic-replicon constructs. pSGR-JCH1 and pSGR-JCH4 were constructed based on pSGR-JFH1 (19, 21). pSGR-J6CF was also constructed from pJ6CF (a kind gift from Jens Bukh) (49), using the same method used to construct pSGR-JFH1. Plasmids used in luciferase assays were constructed based on pSGR-JFH1/Luc (20). Chimeric replicons were constructed by substitution of the corresponding regions. For convenience, several restriction enzyme recognition sites (ClaI [2275], EcoT221 [3639], and BsrGI [6127]) were introduced into the pSGR-J6CF sequence via nucleotide substitutions. The substitutions of the corresponding regions were achieved as follows, with the 5' untranslated region (5'UTR) inserted between NotI and AgeI: NS3, PmeI-EcoT221; NS3 protease, PmeI-ClaI; NS3 helicase, ClaI-EcoT221; NS4, EcoT221-MunI; NS5A, MunI-BsrGI; NS5B, BsrGI-StuI; and 3'UTR, StuI-XbaI (see Fig. 2A and 3A). pSGR-JCH1/Luc and pSGR-JCH4/Luc were also constructed using the same procedure as that for pSGR-JFH1/Luc (20, 21). The Con1 replicon (pSGR-Con1/Luc) was

* Corresponding author. Mailing address: Department of Virology II, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku, Tokyo 162-8640, Japan. Phone: 81-3-5285-1111. Fax: 81-3-5285-1161. E-mail: wakita@nih.go.jp.

[∇] Published ahead of print on 23 May 2007.




FIG. 1. G418-resistant colony formation of JFH-1, J6CF, JCH-1, and JCH-4. Subgenomic RNAs were synthesized *in vitro*, using pSGR-JFH1, pSGR-J6CF, pSGR-JCH1, and pSGR-JCH4 as templates. Transcribed subgenomic RNAs were electroporated into Huh7 cells, and cells were cultured with G418 for 3 weeks before staining with crystal violet as described in Materials and Methods. JFH-1 subgenomic RNA (0.1 μ g) and 10 μ g of J6CF, JCH-1, and JCH-4 subgenomic RNAs were transfected into Huh7 cells. Experiments were performed in triplicate, and representative staining examples are shown.

constructed from pFK-1389/neo/NS3-3'/wt (a kind gift from Ralf Bartenschlager) (32), and the H77c replicon (pSGR-H77c/Luc) was constructed from pCV-H77c (a kind gift from Robert H. Purcell) (50). For convenience, ClaI (2275) and BsrGI (6127) recognition sites were introduced into the pSGR-Con1/Luc and pSGR-H77c/Luc sequences via nucleotide substitutions. Substitutions of the NS3 helicase region and NS5X regions were performed as described above.

Full-length genomic HCV constructs. Plasmids used in the analysis of genomic RNA replication were constructed based on pJFH1 (48) and pJ6CF (49). For convenience, several restriction enzyme recognition sites (ClaI [3929], EcoT221 [5293], and BsrGI [7781]) were introduced into the J6CF sequence via nucleotide substitutions. Substitutions of the NS3 helicase regions were performed by replacement of the ClaI-EcoT221 fragment, substitutions of the NS5X regions were performed by replacement of the BsrGI-XbaI fragment, substitutions of the NS5B regions were performed by replacement of the BsrGI-StuI fragment, and a substitution of the 3'UTR was performed by replacement of the StuI-XbaI fragment (see Fig. 5A).

RNA synthesis and transfection. RNA synthesis and transfection were performed as described previously (48). In brief, plasmids were linearized with XbaI, treated with mung bean nuclease (New England Biolabs, Ipswich, MA), and purified. Linearized, purified DNAs were used as templates for *in vitro* RNA synthesis using a MEGAscript T7 kit (Ambion, Austin, TX) in accordance with the manufacturer's instructions. Synthesized RNA was treated with DNase I (Ambion), followed by purification using ISOGEN-LS (Nippon Gene, Tokyo, Japan). The quality of synthesized RNA was examined by agarose gel electrophoresis. Ten micrograms of *in vitro*-synthesized RNA was used for each electroporation. Trypsinized Huh7 cells (3×10^6 cells) were washed with Opti-MEM I (Invitrogen, Carlsbad, CA) and resuspended in Cytomix buffer (47). RNA was mixed with 400 μ l of cell suspension, and the mixture was then transferred to an electroporation cuvette (Precision Universal Cuvettes, Thermo Hybaid, Middlesex, United Kingdom). The cells were then pulsed at 260 V and 950 μ F using a Gene Pulser II apparatus (Bio-Rad, Hercules, CA). Transfected cells were immediately transferred to 10-cm culture dishes or six-well plates, each containing culture medium, and incubated at 37°C under 5% CO₂. Luciferase mRNA was synthesized from luciferase T7 control DNA (Promega, Madison, WI) by using a mMESSAGE mMACHINE T7 kit (Ambion). To monitor transfection efficiency, *in vitro*-synthesized luciferase RNA was cotransfected with HCV RNA and luciferase activity measured at 4 h after transfection.

G418-resistant colony formation assay. The G418-resistant colony formation assay was performed as described previously (19). In brief, 0.1 μ g or 10 μ g of transcribed RNAs was transfected into 3×10^6 Huh7 cells by electroporation. Transfected cells were immediately transferred to 10-cm culture dishes containing 10 ml of culture medium. G418 (1.0 mg/ml) (Nakalai Tesque, Kyoto, Japan) was added to the culture medium at 16 to 24 h after transfection. Culture medium supplemented with G418 was replaced every 3 days. Three weeks after transfection, cells were fixed with buffered formalin and stained with crystal violet.

Luciferase reporter assay. The luciferase activities of the JFH-1 subgenomic replicon and chimeras in Huh7 cells were measured as described previously (20). Briefly, 5 μ g of transcribed RNAs was transfected into 3×10^6 Huh7 cells by electroporation. Transfected cells were immediately resuspended in culture medium and seeded into six-well culture plates. Cells were harvested serially at 4, 24, and 48 h after transfection and lysed with 200 μ l of cell culture lysis reagent

(Promega). Debris was then removed by centrifugation. Luciferase activity was quantified using a Lumat LB9507 luminometer (EG & G Berthold, Bad Wildbad, Germany) and a luciferase assay system (Promega). Assays were performed three times independently, with each value corrected for transfection efficiency as determined by measuring luciferase activity 4 h after transfection. The data are expressed as relative luciferase units (RLU).

Quantification of HCV core protein. To estimate the concentration of HCV core protein in the culture medium, we performed an HCV core enzyme-linked immunosorbent assay (Ortho-Clinical Diagnostics, Tokyo, Japan) in accordance with the manufacturer's instructions.

Northern blot analysis. Northern blot analysis was performed as described previously (48). In brief, total cellular RNA from HCV RNA-transfected cells was extracted using ISOGEN (Nippon Gene) in accordance with the manufacturer's instructions. Isolated RNA (2 μ g) was separated on a 1% agarose gel containing formaldehyde, transferred to a Hybond N+ positively charged nylon membrane (GE Healthcare, Piscataway, NJ), and immobilized using a Stratilinker UV cross-linker (Stratagene, La Jolla, CA). Hybridization was performed with [α -³²P]dCTP-labeled DNA by using Rapid-Hyb buffer (GE Healthcare). The DNA probe was synthesized using the NS5B-to-3'X fragment of JFH1 excised from pJFH1 by BsrGI and XbaI and labeled using the Megaprime DNA labeling system (GE Healthcare).

Infection of cells with secreted HCV and determination of infectivity. Culture medium from RNA-transfected cells was collected at 72 h posttransfection. Huh7 cells were seeded at a density of 1×10^4 cells per well in poly-D-lysine-coated 96-well plates (CORNING, Corning, NY). On the following day, the collected culture media were serially diluted and used for inoculation of the seeded cells, and the plates were incubated for another 3 days at 37°C. The cells were fixed in methanol for 15 min at -20°C, and the infected foci were visualized by immunofluorescence as described below.

Cells were blocked for 1 h with BlockAce (Dainippon Sumitomo Pharma, Osaka, Japan) supplemented with 0.3% Triton X-100 and then washed with phosphate-buffered saline, followed by incubation with anti-core antibody at 50 μ g/ml in BlockAce. After incubation for 1 h at room temperature, the cells were washed and incubated with a 1:400 dilution of AlexaFluor 488-conjugated anti-mouse immunoglobulin G (Molecular Probes, Eugene, OR) in BlockAce. The cells were then washed and examined using fluorescence microscopy (Olympus, Tokyo, Japan). Infectivity was quantified by counting the infected foci and expressed as numbers of focus-forming units per milliliter (FFU/ml).

RESULTS

G418-resistant colony formation of JFH-1, J6CF, and other genotype 2a subgenomic replicons. First, to compare the replication efficiencies of the JFH-1 and J6CF strains, we performed a G418-resistant colony formation assay with JFH-1 and J6CF RNAs by using subgenomic replicons. The JFH-1 subgenomic replicon formed many colonies with transfection of only 0.1 μ g RNA, but the J6CF subgenomic replicon formed no colonies, even with transfection of 10 μ g RNA (Fig. 1). We also tested




FIG. 2. Luciferase activities of chimeric replicons with a JFH-1 backbone. (A) Structures of chimeric subgenomic replicons with a JFH-1 backbone. The restriction enzyme recognition sites used for the construction of plasmids are indicated. P, PmeI; C, ClaI; E, EcoT22I; M, MunI; B, BsrGI; S, StuI; X, XbaI; wt, wild type. (B) Subgenomic RNAs were synthesized *in vitro* from wild-type or chimeric replicon constructs. Transcribed subgenomic RNAs (5 μ g) were electroporated into Huh7 cells, and cells were harvested serially at 4, 24, and 48 h after transfection. The harvested cells were lysed, and then luciferase activities in the cell lysates were measured. The assays were performed three times independently and the results expressed as luciferase activities (RLU). Each value was corrected for transfection efficiency as determined by measuring the luciferase activity 4 h after transfection. Data are presented as means and standard deviations for luciferase activity at 24 h (white bars) and 48 h (gray bars) after transfection.

other genotype 2a clones (the JCH-1 and JCH-4 strains), which were isolated from patients with chronic hepatitis C (21). Their subgenomic replicons did not form colonies either. Given that chimeric J6/JFH-1 RNA that has the J6 structural-protein-coding

regions and JFH-1 nonstructural-protein-coding regions reportedly replicates autonomously and produces infectious HCV particles (30, 39), we hypothesized that some of the JFH-1 nonstructural-protein-coding regions are important for JFH-1 replication.

Regions of JFH-1 essential for replication. In order to determine which regions of JFH-1 are important for JFH-1 RNA replication, we constructed a series of chimeric JFH-1 subgenomic replicons replacing the 5'UTR, NS3, NS4AB, NS5A, and NS5B-to-3'X (N5BX) regions from the J6CF strain and tested their replication abilities. For this analysis, we adopted luciferase replicon systems (20) because colony formation assays are time-consuming to perform and it is difficult to evaluate precise replication levels using this method. Furthermore, efficient JFH-1 RNA replication may reduce cellular growth, thus affecting colony formation efficiency (34). We constructed JFH-1 chimeric subgenomic luciferase replicons with the J6CF clone because this clone was reportedly infectious in a chimpanzee (49). However, the JCH-1 and JCH-4 clones were not tested for infectivity. The 5'UTR, NS3, NS4AB, NS5A, or N5BX sequences of the JFH-1 replicon were replaced by J6CF sequences (5'UTR-J6, NS3-J6, NS4-J6, NS5A-J6, or N5BX-J6, respectively [Fig. 2A]). The luciferase activities of these replicons are shown in Fig. 2B. The JFH-1 subgenomic replicon replicated efficiently and had a luciferase activity of approximately 10^7 RLU (Fig. 2B, JFH-1 wt). GND, which was replication incompetent because of a mutation at the GDD motif in the NS5B region, had a luciferase activity of only 10^3 RLU (Fig. 2B, JFH-1/GND), which was taken as the background level. The J6CF subgenomic replicon did not replicate and had the same luciferase activity as GND (Fig. 2B, J6CF wt). Replacement of the 5'UTR, NS4AB, and NS5A sequences of JFH-1 by J6CF sequences (5'UTR-J6, NS4-J6, and NS5A-J6, respectively) did not reduce replication (Fig. 2B, 5'UTR-J6 and NS4-J6) or reduced it only slightly (Fig. 2B, NS5A-J6). However, there was no replication for the JFH-1 chimera with J6 N5BX (Fig. 2B, N5BX-J6). In addition, the JFH-1 chimera with the J6 NS3 region (NS3-J6) had a replication level that was more than 10-fold lower at 24 h and around 10-fold lower at 48 h than that of the wild-type JFH-1 replicon (Fig. 2B, JFH-1 wt and NS3-J6). These data show that the JFH-1 NS5B-to-3'X region is essential for JFH-1 RNA replication and indicate that the JFH-1 NS3 region is also important for JFH-1 RNA replication.

Involvement of the NS3 helicase region in efficient JFH-1 replication. The JFH-1 chimera with the J6 NS3 region (NS3-J6) reduced the replication level (Fig. 2B, NS3-J6). The NS3 protein is known to have two domains: a protease domain at the amino terminal one-third and a helicase domain at the carboxyl terminal two-thirds. To determine which region is important for replication, we compared the replication activity of a JFH-1 chimera with that of the NS3 protease-coding region of J6CF (N3P-J6) and that of a JFH-1 chimera with that of the NS3 helicase-coding region of J6CF (N3H-J6) (Fig. 2A, JFH-1/N3P-J6 and JFH-1/N3H-J6). Although N3P-J6 had the same luciferase activity as JFH-1, N3H-J6 had lower activity than JFH-1 (Fig. 2B, N3P-J6 and N3H-J6). These data show that the JFH-1 NS3 helicase-coding region has an important role in JFH-1 replication.

Importance of the JFH-1 NS5B-coding region and 3'UTR in replication. The JFH-1 chimera with J6 N5BX completely abolished replicon replication (Fig. 2B, N5BX-J6). The N5BX region contains two regions, the NS5B protein-coding region and the 3'UTR. The NS5B protein-coding region encodes RNA-dependent RNA polymerase. To analyze which region of

N5BX is important for replication, we separated N5BX into two regions, that is, the NS5B-coding region and the 3'UTR. JFH-1 replicons with NS5B or with the 3'UTR of J6 were constructed (Fig. 2A, JFH-1/NS5B-J6 and JFH-1/3'UTR-J6) and their replication abilities analyzed. The replication level of JFH-1/NS5B-J6 was reduced more than 100-fold compared with that of the wild-type JFH-1 replicon at 48 h (Fig. 2B, N5B-J6). JFH-1/3'UTR-J6 replicated similarly to JFH-1 at 48 h, but the replication activity at 24 h was reduced more than 10-fold compared with that of the original JFH-1 replicon (Fig. 2B, 3'UTR-J6). These data indicate that the NS5B-coding region and the 3'UTR of JFH-1 are both involved in efficient JFH-1 replication.

Rescue of J6CF replicon replication by incorporation of the JFH-1 sequences. Because the JFH-1 N5BX region appeared to be essential for JFH-1 replication (Fig. 2B, N5BX-J6), we tested whether JFH-1 N5BX could restore the replication of J6CF RNA. We constructed a chimeric J6CF subgenomic replicon containing the JFH-1 N5BX region (Fig. 3A, J6/N5BX-JFH1) and tested its replication abilities. The luciferase activity of J6CF subgenomic RNA was recovered by inclusion of JFH-1 N5BX (Fig. 3B, N5BX-JFH1), but this chimeric replicon showed lower replication activity than the original JFH-1 replicon (Fig. 3B, JFH-1 wt). Furthermore, J6CF replication was not restored by only JFH-1 NS5B (J6/N5B-JFH1) or only the 3'UTR (J6/3'UTR-JFH1) (Fig. 3B, N5B-JFH1 or 3'UTR-JFH1, respectively). These observations clearly indicate that the JFH-1 NS5B-to-3'X region is essential, and the NS5B-coding region and 3'UTR are both important for efficient RNA replication in Huh7 cells. However, other JFH-1 regions are also involved in efficient replication.

The JFH-1 NS3 helicase-coding region was also important for efficient replication, and we thus tested whether the JFH-1 NS3 helicase region by itself could restore J6CF replication (as occurred for the JFH-1 N5BX region). Insertion of only the NS3 helicase region of JFH-1 into J6CF (Fig. 3A, J6/N3H-JFH1) did not restore replication (Fig. 3B, N3H-JFH1). However, replication of the J6 chimeric replicon seemed considerably restored by insertion of JFH-1 NS5B or the 3'UTR in addition to the NS3 helicase-coding region (Fig. 3B, N3H+N5B-JFH1 or N3H+3'UTR-JFH1, respectively) and fully restored by insertion of the JFH-1 NS3 helicase region and JFH-1 N5BX region (Fig. 3B, N3H+N5BX-JFH1). These results indicate that the JFH-1 N5BX region is essential for subgenomic-replicon replication and that the JFH-1 NS3 helicase-coding region has an additional role in replication. This was also confirmed by analysis of the replication abilities of JFH-1 replicons with double substitutions of J6CF (Fig. 2A, JFH-1/N3H+N5B-J6, JFH-1/N3H+3'UTR-J6, and JFH-1/N3H+N5BX-J6). Neither of these chimeric JFH-1 replicons replicated (Fig. 2B, N3H+N5B-J6, N3H+3'UTR-J6, and N3H+N5BX-J6).

The NS3 helicase and NS5B-3'X regions of JFH-1 can restore the replication of genotype 2a replicons but not of genotype 1 replicons. To test whether the JFH-1 NS3 helicase and N5BX regions could restore other HCV replicon replication, chimeric replicon constructs N3H-JFH1, N5BX-JFH1, and N3H+N5BX-JFH1 were constructed using two genotype 2a replicons (JCH-1 and JCH-4), a genotype 1a replicon (H77c), and a genotype 1b replicon (Con1), respectively. The




FIG. 3. Luciferase activities of chimeric replicons with a J6CF backbone. (A) Structures of chimeric subgenomic replicons with a J6CF backbone. The restriction enzyme recognition sites used for the construction of plasmids are indicated. C, ClaI; E, EcoT22I; B, BsrGI; S, StuI; X, XbaI; wt, wild type. (B) Wild-type or chimeric subgenomic RNAs were transfected into Huh7 cells, and the luciferase activities of the transfected cells were examined as described in the legend to Fig. 2B. Assays were performed three times independently, and data are presented as means and standard deviations for luciferase activity (RLU) at 24 h (white bars) and 48 h (gray bars) after transfection.

replication level of each wild-type and chimeric replicon was evaluated by luciferase activity measurement after transient transfection of replicon RNA. No replication of any of the wild-type replicons (Fig. 4, JCH-1 wt, JCH-4 wt, H77c wt, and Con1 wt) or of any of the replicons with insertion of the JFH-1 NS3 helicase region (Fig. 4, JCH-1/N3H-JFH1, JCH-4/N3H-

JFH1, H77c/N3H-JFH1, and Con1/N3H-JFH1) was detected. However, genotype 2a replicons with insertion of the JFH-1 N5BX region increased their replication levels severalfold at 48 h (Fig. 4, JCH-1/N5BX-JFH1 and JCH-4/N5BX-JFH1). Furthermore, insertion of both the N3H and the N5BX regions increased the JCH-1 replication over 10-fold compared to that




FIG. 4. Restoration of genotype 2a and genotype 1 replicon replication by the insertion of JFH-1 sequences. Two genotype 2a replicons, JCH-1 and JCH-4, a genotype 1a replicon, H77c, and a genotype 1b replicon, Con-1, were used in this assay. Three kinds of chimeric replicons, N3H-JFH-1, N5BX-JFH1, and N3H+N5BX-JFH-1, were prepared for all four HCV replicons. Wild-type (wt) or chimeric subgenomic RNAs were transfected into Huh7 cells and the luciferase activities of the transfected cells examined as described in the legend to Fig. 2B. The assays were performed three times independently, and data are presented as means and standard deviations for luciferase activity (RLU) at 24 h (white bars) and 48 h (gray bars) after transfection.

of wild-type JCH-1 at 48 h and recovered the JCH-4 replication to a level similar to that of wild-type JFH-1 at 48 h (Fig. 4, JCH-1/N3H+N5BX-JFH1 and JCH-4/N3H+N5BX-JFH1, respectively). On the other hand, insertion of the JFH-1 N5BX region or both the N3H and the N5BX regions did not restore H77c or Con1 replicon replication (Fig. 4, H77c/N5BX-JFH1, H77c/N3H+N5BX-JFH1, Con1/N5BX-JFH1, and Con1/N3H+N5BX-JFH1). HCV polyprotein processing is critically important for HCV RNA replication and virus production, and this processing may be affected by the chimeric RNA molecules between different isolates of genotype 2 as well as those between genotypes 1 and 2. However, our data indicated that HCV polyprotein processing did not differ among the chimeric constructs (data not shown). Thus, the JFH-1 N3H and N5BX regions can rescue the replication of genotype 2a replicons at different levels but not the replication of genotype 1 replicons.


The NS3 helicase and NS5B-3'X regions are both important for JFH-1 genomic RNA replication. Next, we applied the previously described results to genomic RNA replication. The structures of HCV, the template DNA for JFH-1, and the chimeric full-genomic RNAs are shown in Fig. 5A. Full-length HCV RNAs were synthesized as described above and their quality and integrity then confirmed by gel electrophoresis (data not shown). To analyze the transient RNA replication of these chimeric RNAs in Huh7 cells, the synthesized RNAs were transfected into Huh7 cells and total RNA was extracted from HCV RNA-transfected cells at various time points. Northern blot analysis was then performed. The equality of the transfection efficiencies was confirmed by the cotransfection of luciferase mRNA (data not shown). As shown in Fig. 5B, JFH-1 RNA decreased at 10 h after transfection but replicated

efficiently at 24 to 48 h after transfection, as described previously (48). J6 chimeric RNA with the NS3 helicase and N5BX regions of JFH-1 (J6/N3H+N5BX-JFH1) replicated with similar kinetics but with lower efficiency. J6 chimeric RNA with JFH-1 N5BX (J6/N5BX-JFH1) showed no replication in this assay, like J6CF or JFH-1 GND, although this chimera replicated to a considerable extent in subgenomic-replicon assays. Taken together, these data indicate that the NS3 helicase-coding region and the NS5B-to-3'X region of JFH-1 are both essential for full-length genomic HCV RNA replication in Huh7 cells.


Core protein and infectious-chimeric-virus secretion from chimeric J6CF RNA-transfected cells. Finally, we tested whether chimeric RNA-transfected cells could secrete infectious virus particles. Figure 5C shows the core protein secretion into the culture medium from JFH-1, JFH-1/GND, J6CF, and chimeric-RNA-transfected cells. Core protein was efficiently secreted from cells transfected with JFH-1 RNA (Fig. 5C and Table 1) and those transfected with J6/N3H+N5BX-JFH1 RNA, but with efficiencies lower than that for JFH-1 (Fig. 5C and Table 1). J6/N5BX-JFH1, JFH-1/GND, and J6CF RNA-transfected cells, which showed no RNA replication by Northern blot analysis (Fig. 5B), did not secrete core proteins into the culture medium (Table 1). By the replicon assay, JFH-1/N5BX-J6 showed no replication in Huh7 cells (Fig. 2B, N5BX-J6), and full-length JFH-1/N5BX-J6 RNA-transfected cells did not secrete core protein into the culture medium (Table 1). On the other hand, JFH-1/N5B-J6 replicated to some extent in the replicon assay (Fig. 2B, N5B-J6), and full-length JFH-1/N5B-J6 RNA-transfected cells secreted a smaller amount of core protein than JFH-1 RNA-transfected cells (Fig. 5C and Table 1). Both JFH-1/N3H-J6 and JFH-1/3'UTR-J6 RNA-transfected cells secreted about half the amount of core protein than the JFH-1 RNA-transfected cells did (Fig. 5C and Table 1); however, the replication level of the JFH1/N3H-J6 replicon was markedly lower than those of the JFH-1 and JFH-1/3'UTR-J6 replicons (Fig. 2B, JFH-1 wt, N3H-J6, and 3'UTR-J6), and the replication level of full-length JFH-1/N3H-J6 RNA was also lower than those of the JFH-1 and JFH-1/3'UTR-J6 RNAs as determined by Northern blot analysis (data not shown). Transfection of the other two chimeric RNAs, JFH-1/N3H+N5B-J6 and JFH-1/N3H+N5BX-J6, did not induce core protein secretion (Table 1), and this is in agreement with the finding that neither chimeric replicon replicated (Fig. 2B, N3H+N5B-J6 and N3H+N5BX-J6).

Then, we tested the infectivity of the culture medium from the RNA-transfected cells by a focus formation assay. The infectivity of the culture medium from JFH-1 RNA-transfected cells was determined as $8.8 \times 10^3 \pm 5.7 \times 10^2$ FFU/ml (Table 1). The infectivity of the culture medium was also detected from cells transfected with J6/N3H+N5BX/JFH-1, JFH1/N3H-J6, JFH-1/N5B-J6, or JFH-1/3'UTR-J6 RNA but not with other chimeric RNAs (Table 1). This result thus indicates that efficient core protein secretion is at least indispensable for infectious-virus secretion. However, the levels of infectivity of culture medium did not correlate with core protein concentrations. In particular, JFH-1/N3H-J6 RNA-transfected cells secreted a rather higher level of core protein, but its infectious titer was low. The RNA replication capacity of JFH-1/N3H-J6 was lower than that of wild-type JFH-1 or JFH-1/3'UTR-J6

A



B



C




TABLE 1. Infectious titers of the media from chimeric HCV RNA-transfected cells

Construct ^a	Core protein level (fmol/ml)	Infectivity (FFU/ml)
JFH-1 (wild type)	50.7 ± 4.1	8.8 × 10 ³ ± 5.7 × 10 ²
JFH-1/GND	0	0
J6CF (wild type)	0	0
J6/N5BX-JFH1	0	0
J6/N3H+N5BX-JFH1	7.7 ± 1.7	9.1 × 10 ¹ ± 4.1 × 10 ¹
JFH-1/N3H-J6	26.3 ± 3.6	1.7 × 10 ¹ ± 1.2 × 10 ¹
JFH-1/N5B-J6	0.1 ± 0.0	6.7 × 10 ⁰ ± 4.1 × 10 ⁰
JFH-1/3'UTR-J6	23.6 ± 2.9	2.6 × 10 ³ ± 7.1 × 10 ²
JFH-1/N5BX-J6	0	0
JFH-1/N3H+N5B-J6	0	0
JFH-1/N3H+N5BX-J6	0	0

^a Culture media were collected from the RNA-transfected cells 72 h after transfection.

(Fig. 2B), and currently, there is no clear explanation for this discrepancy. This will be further examined in a future study.

Importantly, we found that the J6/N3H+N5BX-JFH1 chimera produced infectious virus. These results strongly indicate that the NS3 helicase and NS5B-to-3'X regions of JFH-1 are important for autonomous replication of the replication-incompetent J6CF strain and for secretion of infectious chimeric virus, although the virus secretion efficiency and the infection efficiency of the secreted virus were low.

DISCUSSION

In the present study, we identified the regions that are important for efficient JFH-1 replication in Huh7 cells by using chimeric constructs with other genotype 2a clones. Via transient replication assays of JFH-1 and J6CF chimeras, both the NS3 helicase-coding (N3H) region and the NS5B-to-3'X (N5BX) region of JFH-1 were found to be important for replication (Fig. 2 and 3). This was also confirmed by full-length genomic RNA replication, but the replication level of J6/N3H+N5BX-JFH1 was lower than that of wild-type JFH-1 (Fig. 5B). The N5BX region of JFH-1 was the minimum essential region for subgenomic-replicon replication (Fig. 3B, N5BX-JFH-1), but in full-length RNA replication, the NS3 helicase-coding region of JFH-1 was also necessary (Fig. 5B). This contradiction might be explained by differences in RNA length, because shorter RNAs such as subgenomic replicons are likely to replicate even with a less powerful replication engine. Alternatively, there could be some negative element for replication in the J6CF structural-protein-coding region or some positive element in the *neo* encephalomyocarditis virus

internal ribosome entry site region of the subgenomic replicon. Furthermore, J6 chimeric RNA with the minimum essential regions of JFH-1 (J6/N3H+N5BX-JFH1) caused Huh7 cells to secrete infectious chimeric virus particles. However, the infection efficiency of J6/N3H+N5BX-JFH1 was lower than that of wild-type JFH-1. First, this may be due to the low RNA replication level. With JFH-1 NS3 helicase and N5BX, J6CF was able to replicate, but the replication efficiency was lower than that of JFH-1 (Fig. 5B). Because J6CF replication could occur only with JFH-1 NS3 helicase and N5BX, more *cis*-acting replication elements (CREs) of JFH-1 may be needed for more efficient replication of J6CF. Second, the levels of virus assembly may be low. This chimera had only the NS3 helicase, NS5B, and 3'UTR regions of JFH-1, possibly omitting some regions important for efficient virus particle secretion. Given that the NS2 region of JFH-1 is reportedly important in virus assembly and release (39), the NS2 region may be a possible candidate. JFH-1/N3H-J6 RNA-transfected cells secreted a substantial amount of core protein; however, its infectivity was much lower (Table 1). The JFH-1 N3H region may be important for the infectivity of the secreted virus and/or for virus particle secretion itself. This will be determined in a future study.

Significance of JFH-1 N5BX for replication. We demonstrated the importance of both the NS5B-coding region and the 3'UTR in JFH-1 replication in the present study. There are several reports regarding CREs within the NS5B-coding region and 3'UTR of Con1 (9, 28, 52). The importance of the interaction between CREs in NS5B and the 3'UTR for replication has also been reported for the Con1 strain (9). The nucleotide sequences involved in the kissing-loop interaction were conserved between JFH-1, J6CF, and Con-1. However, mutations in other regions may affect this interaction by disrupting the RNA secondary structures. On the other hand, given that the NS5B-coding region encodes an RNA-dependent RNA polymerase, the enzymatic activities of the polymerase may differ among the tested strains. The sequence similarities of the JFH-1 and J6CF NS5B regions are 92.2% for the nucleotide sequence and 95.1% for the amino acid sequence. Out of 591 amino acids, only 29 amino acids differ, and the GDD motif that is highly conserved among RdRps is conserved. There are many reports regarding the interaction between NS5B and other viral or cellular proteins, and some of the interactions have been reported to play a role in replication (6, 10, 12, 15, 17, 27, 41–43, 45, 46). Furthermore, the importance of the membrane localization of NS5B with respect to replication has also been reported (29, 35). Mutations in J6CF NS5B may affect these roles. It is thus important to examine the RdRp activities of JFH-1 and J6CF NS5B proteins *in vitro*.

FIG. 5. Analysis of transient replication of genomic chimeric HCV RNA. (A) Structures of full-length chimeric HCV RNAs. Each chimeric full-length construct was prepared by the insertion of the restricted fragments as indicated. The restriction enzyme recognition sites used for the plasmid constructions are indicated. C, ClaI; E, EcoT22I; B, BsrGI; S, StuI; X, XbaI; wt, wild type. (B) Northern blot analysis of total RNA prepared from cells transfected with transcribed genomic HCV RNA. Numbers of synthetic JFH-1 RNA (control RNA), RNA isolated from naïve cells (Huh7), and hours after transfection (4, 10, 24, 48, and 72) are indicated. Arrowheads indicate full-length HCV RNA (HCV RNA) and 28S rRNA (28S). A representative autoradiogram (6-h exposure) of three independent experiments is presented. (C) HCV core protein secretion from the RNA-transfected cells. Transcribed wild-type or chimeric full-length HCV RNAs (10 µg) were transfected into Huh7 cells. Culture medium was harvested at 4, 10, 24, 48, and 72 h after transfection. The amounts of core proteins in the harvested culture medium were measured using an HCV core enzyme-linked immunosorbent assay. The assays were performed five times independently, and data are presented as means and standard deviations.

On the other hand, the effect of the 3'UTR is very surprising, especially since the nucleotide sequences of this region are very similar between JFH-1 and J6CF. In this study, the 3'UTR includes four parts: 22 nucleotides at the 3'-end NS5B region (as a result of the cloning strategy), 39 nucleotides of variable region, the poly(U/UC) region, and a 98-nucleotide 3'X region. There are a single synonymous nucleotide mutation in the 3'-end NS5B region and three nucleotide mutations in the variable region. The poly(U/UC) regions are 99 and 132 nucleotides in JFH-1 and J6CF, respectively. There are no mutations in the 3'X region in either strain. It is thus quite interesting to pursue the mechanisms of these mutations in the 3'UTR that affect the HCV RNA replication levels. Further studies are important for precise elucidation of the efficient replication mechanisms of JFH-1.

Significance of the JFH-1 NS3 helicase region for replication. In the present study, we demonstrated the importance of the JFH-1 NS3 helicase region, especially in full-length genomic RNA replication. It has been reported that an active NS3 helicase is required for replication of subgenomic replicons (25). The NS3 helicase domain possesses helicase activity and ATPase activity, and it has been reported that the characters of these enzymes differ among the genotypes and the strains (26). NS3 has also been reported to interact with positive- and negative-strand RNA 3'UTRs (1). One possible model of the role of NS3 in RNA replication is that NS3 helicase unwinds RNA secondary structures and/or a double-stranded RNA intermediate before RNA synthesis by NS5B (37). The sequence similarity of the NS3 helicase regions of JFH-1 and J6CF is rather high, 89.5% for the nucleotide sequence and 93.8% for the amino acid sequence, and out of 487 amino acids, only 30 amino acids differ. These mutations may affect the enzymatic activities of NS3 helicase.

Furthermore, it has been reported that NS3 can stimulate NS5B RdRp activity (38). It has also been reported that the NS3 protease domain and NS5B stimulate NS3 helicase activity (53). Taken together, these findings show that not only the enzymatic activities themselves but also the combination or interaction of the NS3 and NS5B proteins could be important. However, it is still important to examine and compare the NS3 helicase enzymatic activities in vitro of JFH-1 and other HCV strains in a further study.

Replication in vitro and in vivo. We previously reported that JFH-1 RNA could replicate efficiently in Huh7 cells. Cell-cultured JFH-1 virus was also found to be infectious in chimpanzees; however, the virus was cleared immediately after transient viremia (48). In contrast, J6CF does not replicate in Huh7 cells, but it is infectious in chimpanzees (49). J6/JFH-1 chimeric RNA replicated efficiently in Huh7 cells (39) and Huh7-derived cell lines (30), and cell-cultured chimeric J6/JFH-1 virus was infectious in chimpanzees and in chimeric uPA-SCID mice (31). Replication efficiency in vitro may not necessarily correlate with that in vivo. The H77, Con-1, and HCV-N strains were infectious in chimpanzees (3, 5, 23, 50). However, the H77 and Con-1 strains need adaptive mutations for efficient replication in cultured cells (4, 24) and HCV-N replicates relatively efficiently in cultured cells (16). On the other hand, H77-S containing five adaptive mutations can produce infectious virus particles (51), but the Con-1 and HCV-N strains do not produce virus particles (16, 40). It is still unclear

what viral or host factors are important for efficient replication and infectious-virus production in vitro and in vivo. However, understanding HCV replication mechanisms by using cell culture models is still important for elucidation of the HCV life cycle.

Significance of the regions responsible for JFH-1 replication. Using two HCV strains, JFH-1 and J6CF, which are very closely related but have different characteristics, we were able to determine which regions are important for replication in cultured cells. Replication of two other genotype 2a strains, JCH-1 and JCH-4, was also recovered by replacement of the N3H and N5BX regions of JFH-1 at the lower levels compared to replication of the J6 replicon (Fig. 3B and 4). This may be because J6CF is an infectious clone in chimpanzees, but the JCH-1 and JCH-4 strains are clinical isolates from chronic-hepatitis patients (21) and may include critical mutations in other important regions. Furthermore, replication of genotype 1 HCV replicons was not restored by the same procedure as that for genotype 2a replicons (Fig. 4). Functional complementation in the nonstructural region and 3'UTR may be difficult beyond the genotypes.

Obtaining virus particles is an important step in antiviral research. Although infection efficiency is improved in permissive cell lines, most HCV strains still cannot replicate or produce virus particles in cultured cells. Therefore, chimeric virus particles with the JFH-1 replication engine may be suitable substitutes. Furthermore, analyses using chimeric viruses that have structural proteins and other regions from various strains may give us new information regarding strain-specific effects on HCV life cycles. Consequently, applying the findings of the present study to replication-incompetent strains may be useful not only for analyses of virus strain specificity and precise analyses of the HCV life cycle but also for antiviral studies.

In conclusion, we analyzed the mechanism underlying efficient JFH-1 replication by using intragenotypic chimeras of JFH-1 and J6CF and clearly showed the importance of the JFH-1 NS3 helicase region and the NS5B-to-3'X region for efficient replication of HCV genotype 2a strains.

ACKNOWLEDGMENTS

A.M. is supported by the Viral Hepatitis Research Foundation of Japan, and K.M. is supported by the Japan Health Sciences Foundation. This work was partially supported by a grant-in-aid for Scientific Research from the Japan Society for the Promotion of Science, from the Ministry of Health, Labor and Welfare of Japan, and from the Ministry of Education, Culture, Sports, Science and Technology and by the Research on Health Sciences Focusing on Drug Innovation from the Japan Health Sciences Foundation.

The pJ6CF plasmid was kindly provided by Jens Bukh. The pCV-H77c plasmid was kindly provided by Robert H. Purcell. The pFK-1389/neo/NS3-3'/wt plasmid was kindly provided by Ralf Bartenschlager.

REFERENCES

1. Banerjee, R., and A. Dasgupta. 2001. Specific interaction of hepatitis C virus protease/helicase NS3 with the 3'-terminal sequences of viral positive- and negative-strand RNA. *J. Virol.* 75:1708-1721.
2. Bartenschlager, R., and V. Lohmann. 2000. Replication of hepatitis C virus. *J. Gen. Virol.* 81:1631-1648.
3. Beard, M. R., G. Abell, M. Honda, A. Carroll, M. Gartland, B. Clarke, K. Suzuki, R. Lanford, D. V. Sangar, and S. M. Lemon. 1999. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. *Hepatology* 30:316-324.
4. Blight, K. J., J. A. McKeating, J. Marcotrigiano, and C. M. Rice. 2003.

- Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. *J. Virol.* 77:3181–3190.
5. Bukh, J., T. Pietschmann, V. Lohmann, N. Krieger, K. Faulk, R. E. Engle, S. Govindarajan, M. Shapiro, M. St. Claire, and R. Bartenschlager. 2002. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. *Proc. Natl. Acad. Sci. USA* 99:14416–14421.
 6. Choi, S. H., K. J. Park, B. Y. Ahn, G. Jung, M. M. Lai, and S. B. Hwang. 2006. Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular I κ B kinase. *Mol. Cell. Biol.* 26:3048–3059.
 7. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244:359–362.
 8. Choo, Q. L., K. H. Richman, J. H. Han, K. Berger, C. Lee, C. Dong, C. Gallegos, D. Coit, R. Medina-Selby, P. J. Barr, et al. 1991. Genetic organization and diversity of the hepatitis C virus. *Proc. Natl. Acad. Sci. USA* 88:2451–2455.
 9. Friebe, P., J. Boudet, J. P. Simorre, and R. Bartenschlager. 2005. Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. *J. Virol.* 79:380–392.
 10. Gao, L., H. Tu, S. T. Shi, K. J. Lee, M. Asanaka, S. B. Hwang, and M. M. Lai. 2003. Interaction with a ubiquitin-like protein enhances the ubiquitination and degradation of hepatitis C virus RNA-dependent RNA polymerase. *J. Virol.* 77:4149–4159.
 11. Grakoui, A., C. Wychowski, C. Lin, S. M. Feinstone, and C. M. Rice. 1993. Expression and identification of hepatitis C virus polypeptide cleavage products. *J. Virol.* 67:1385–1395.
 12. Hamamoto, I., Y. Nishimura, T. Okamoto, H. Aizaki, M. Liu, Y. Mori, T. Abe, T. Suzuki, M. M. Lai, T. Miyamura, K. Moriishi, and Y. Matsuura. 2005. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. *J. Virol.* 79:13473–13482.
 13. Hijikata, M., N. Kato, Y. Ootsuyama, M. Nakagawa, and K. Shimotohno. 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. *Proc. Natl. Acad. Sci. USA* 88:5547–5551.
 14. Hijikata, M., H. Mizushima, Y. Tanji, Y. Komoda, Y. Hirowatari, T. Akagi, N. Kato, K. Kimura, and K. Shimotohno. 1993. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. *Proc. Natl. Acad. Sci. USA* 90:10773–10777.
 15. Hirano, M., S. Kaneko, T. Yamashita, H. Luo, W. Qin, Y. Shiota, T. Nomura, K. Kobayashi, and S. Murakami. 2003. Direct interaction between nucleolin and hepatitis C virus NS5B. *J. Biol. Chem.* 278:5109–5115.
 16. Ikeda, M., M. Yi, K. Li, and S. M. Lemon. 2002. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. *J. Virol.* 76:2997–3006.
 17. Ishido, S., T. Fujita, and H. Hotta. 1998. Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus. *Biochem. Biophys. Res. Commun.* 244:35–40.
 18. Kato, N., M. Hijikata, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, T. Sugimura, and K. Shimotohno. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc. Natl. Acad. Sci. USA* 87:9524–9528.
 19. Kato, T., T. Date, M. Miyamoto, A. Furusaka, K. Tokushige, M. Mizokami, and T. Wakita. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. *Gastroenterology* 125:1808–1817.
 20. Kato, T., T. Date, M. Miyamoto, M. Sugiyama, Y. Tanaka, E. Orito, T. Ohno, K. Sugihara, I. Hasegawa, K. Fujiwara, K. Ito, A. Ozasa, M. Mizokami, and T. Wakita. 2005. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. *J. Clin. Microbiol.* 43:5679–5684.
 21. Kato, T., A. Furusaka, M. Miyamoto, T. Date, K. Yasui, J. Hiramoto, K. Nagayama, T. Tanaka, and T. Wakita. 2001. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. *J. Med. Virol.* 64:334–339.
 22. Kiyosawa, K., T. Sodeyama, E. Tanaka, Y. Gibo, K. Yoshizawa, Y. Nakano, S. Furuta, Y. Akahane, K. Nishioka, R. H. Purcell, et al. 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *Hepatology* 12:671–675.
 23. Kolykhalov, A. A., E. V. Agapov, K. J. Blight, K. Mihalik, S. M. Feinstone, and C. M. Rice. 1997. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. *Science* 277:570–574.
 24. Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. *J. Virol.* 75:4614–4624.
 25. Lam, A. M., and D. N. Frick. 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. *J. Virol.* 80:404–411.
 26. Lam, A. M., D. Keeney, P. Q. Eckert, and D. N. Frick. 2003. Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties. *J. Virol.* 77:3950–3961.
 27. Lan, S., H. Wang, H. Jiang, H. Mao, X. Liu, X. Zhang, Y. Hu, L. Xiang, and Z. Yuan. 2003. Direct interaction between alpha-actinin and hepatitis C virus NS5B. *FEBS Lett.* 554:289–294.
 28. Lee, H., H. Shin, E. Wimmer, and A. V. Paul. 2004. *cis*-Acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome. *J. Virol.* 78:10865–10877.
 29. Lee, K. J., J. Choi, J. H. Ou, and M. M. Lai. 2004. The C-terminal transmembrane domain of hepatitis C virus (HCV) RNA polymerase is essential for HCV replication in vivo. *J. Virol.* 78:3797–3802.
 30. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. *Science* 309:623–626.
 31. Lindenbach, B. D., P. Meuleman, A. Ploss, T. Vanwolleghem, A. J. Syder, J. A. McKeating, R. E. Lanford, S. M. Feinstone, M. E. Major, G. Leroux-Roels, and C. M. Rice. 2006. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. *Proc. Natl. Acad. Sci. USA* 103:3805–3809.
 32. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285:110–113.
 33. McLauchlan, J., M. K. Lemberg, G. Hope, and B. Martoglio. 2002. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. *EMBO J.* 21:3980–3988.
 34. Miyamoto, M., T. Kato, T. Date, M. Mizokami, and T. Wakita. 2006. Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1). *Intervirology* 49:37–43.
 35. Moradpour, D., V. Brass, E. Bieck, P. Friebe, R. Gosert, H. E. Blum, R. Bartenschlager, F. Penin, and V. Lohmann. 2004. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. *J. Virol.* 78:13278–13284.
 36. Nakabayashi, H., K. Taketa, K. Miyano, T. Yamane, and J. Sato. 1982. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. *Cancer Res.* 42:3858–3863.
 37. Paolini, C., R. De Francesco, and P. Gallinari. 2000. Enzymatic properties of hepatitis C virus NS3-associated helicase. *J. Gen. Virol.* 81:1335–1345.
 38. Piccininni, S., A. Varaklioti, M. Nardelli, B. Dave, K. D. Raney, and J. E. McCarthy. 2002. Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein. *J. Biol. Chem.* 277:45670–45679.
 39. Pietschmann, T., A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Drexel, F. L. Cosset, and R. Bartenschlager. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. *Proc. Natl. Acad. Sci. USA* 103:7408–7413.
 40. Pietschmann, T., V. Lohmann, A. Kaul, N. Krieger, G. Rinck, G. Rutter, D. Strand, and R. Bartenschlager. 2002. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. *J. Virol.* 76:4008–4021.
 41. Shimakami, T., M. Hijikata, H. Luo, Y. Y. Ma, S. Kaneko, K. Shimotohno, and S. Murakami. 2004. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. *J. Virol.* 78:2738–2748.
 42. Shimakami, T., M. Honda, T. Kusakawa, T. Murata, K. Shimotohno, S. Kaneko, and S. Murakami. 2006. Effect of hepatitis C virus (HCV) NS5B-nucleolin interaction on HCV replication with HCV subgenomic replicon. *J. Virol.* 80:3332–3340.
 43. Shiota, Y., H. Luo, W. Qin, S. Kaneko, T. Yamashita, K. Kobayashi, and S. Murakami. 2002. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. *J. Biol. Chem.* 277:11149–11155.
 44. Takamizawa, A., C. Mori, I. Fuke, S. Manabe, S. Murakami, J. Fujita, E. Onishi, T. Andoh, I. Yoshida, and H. Okayama. 1991. Structure and organization of the hepatitis C virus genome isolated from human carriers. *J. Virol.* 65:1105–1113.
 45. Tu, H., L. Gao, S. T. Shi, D. R. Taylor, T. Yang, A. K. Mircheff, Y. Wen, A. E. Gorbalenya, S. B. Hwang, and M. M. Lai. 1999. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. *Virology* 263:30–41.
 46. Uchida, M., N. Hino, T. Yamanaka, H. Fukushima, T. Imanishi, Y. Uchiyama, T. Kodama, and T. Doi. 2002. Hepatitis C virus core protein binds to a C-terminal region of NS5B RNA polymerase. *Hepatology* 35:297–306.
 47. van den Hoff, M. J., A. F. Moorman, and W. H. Lamers. 1992. Electroporation in 'intracellular' buffer increases cell survival. *Nucleic Acids Res.* 20:2902.
 48. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11:791–796.
 49. Yanagi, M., R. H. Purcell, S. U. Emerson, and J. Bukh. 1999. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. *Virology* 262:250–263.
 50. Yanagi, M., R. H. Purcell, S. U. Emerson, and J. Bukh. 1997. Transcripts

- from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. *Proc. Natl. Acad. Sci. USA* **94**:8738–8743.
51. Yi, M., R. A. Villanueva, D. L. Thomas, T. Wakita, and S. M. Lemon. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proc. Natl. Acad. Sci. USA* **103**:2310–2315.
52. You, S., D. D. Stump, A. D. Branch, and C. M. Rice. 2004. A *cis*-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. *J. Virol.* **78**:1352–1366.
53. Zhang, C., Z. Cai, Y. C. Kim, R. Kumar, F. Yuan, P. Y. Shi, C. Kao, and G. Luo. 2005. Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase. *J. Virol.* **79**:8687–8697.
54. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. *Proc. Natl. Acad. Sci. USA* **102**:9294–9299.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLMS	IND CLMS
10/558,155	01/03/2007	1645	2230	1254-0299PUS1	21	5

CONFIRMATION NO. 6809

2292

BIRCH STEWART KOLASCH & BIRCH
 PO BOX 747
 FALLS CHURCH, VA 22040-0747

FILING RECEIPT



OC000000025983578

Date Mailed: 09/25/2007

Receipt is acknowledged of this nonprovisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Takaji Wakita, Tokyo, JAPAN;
 Takanobu Kato, Aichi, JAPAN;
 Tomoko Date, Kanagawa, JAPAN;

Assignment For Published Patent Application

TORAY INDUSTRIES, INC, TOKYO, JAPAN
 TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, TOKYO, JAPAN
 RALF BARTENSCHLAGER, SCHRIESHEIM, GERMANY


Power of Attorney: The patent practitioners associated with Customer Number 2292.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/15038 11/25/2003

Foreign Applications

JAPAN 2003-148242 05/26/2003
 JAPAN 2003-329115 09/19/2003



If Required, Foreign Filing License Granted: 09/24/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/558,155**

Projected Publication Date: 01/03/2008

Non-Publication Request: No

Early Publication Request: No

Title

Nucleic Acid Construct Containing a Nucleic Acid Derived From the Genome of Hepatitis C Virus (Hcv) of Genotype 2A, and a Cell Having Such Nucleic Acid Construct Introduced Therein

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).